Mirum and Incyte’s Atebrioz approved for FOP in US
Atebrioz has been developed by Incyte and licensed to Mirum for global commercialisation.
Drug Development
Amberstone and Henlius agree to develop solid-tumour T-cell engagers
FDA approves Lilly’s Onswik for type 2 diabetes in adults
Genialis and Inventia to enhance pancreatic cancer treatment testing
Basecamp Research secures $140m for AI-driven therapies
BoomRay and Novartis sign $900m deal for radioligand therapy
Boehringer and Envisagenics to develop precision cancer therapies in $1bn deal
Made Scientific acquires cell therapy facility in Pennsylvania, US
